Introduction
Product verification is an important part of responsible pharmaceutical use. Patients, healthcare professionals, pharmacies and other authorized pharmaceutical organizations should be able to identify a medicine and establish whether its packaging and documentation are consistent with the product being supplied.
Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib, an oral targeted anticancer medicine belonging to the fibroblast growth factor receptor inhibitor class.
Because pemigatinib is a prescription anticancer medicine, correct product identification is particularly important. A product name or printed strength alone does not establish the authenticity, quality, manufacturing origin or regulatory status of a particular package.
This page explains the information that should be checked when reviewing a Pemitinib product and why independent documentation is necessary.
Understanding Product Identity
A pharmaceutical product has several identifying characteristics. These characteristics should be consistent across its packaging, labeling and official documentation.
Important identifying details include:
- Brand or product name.
- Generic or active ingredient.
- Strength.
- Dosage form.
- Route of administration.
- Manufacturer.
- Manufacturing location, where applicable.
- Marketing authorization holder.
- Batch or lot number.
- Manufacturing date, where provided.
- Expiry date.
- Country-specific registration information.
For Pemitinib, the product identity presented on this website is pemigatinib 13.5 mg. The exact formulation, packaging and legal manufacturer must be established from the specific product’s documentation.
Confirm the Active Ingredient
The active ingredient identified for Pemitinib is pemigatinib.
Pemigatinib is a selective inhibitor of FGFR1, FGFR2 and FGFR3. It is used in specific cancer treatment settings involving relevant genetic abnormalities.
When examining a product package, the active ingredient should be clearly identified. The stated ingredient should agree with the supplied package leaflet and pharmaceutical documentation.
A medicine should not be assumed to contain pemigatinib solely because its name resembles another pemigatinib brand.
Confirm the Strength
The Pemitinib product featured on this website is identified in a stated strength of 13.5 mg.
Strength refers to the amount of active ingredient contained in the dosage unit.
The strength printed on the outer package should agree with the individual tablet labeling and the supplied product information.
A strength mismatch can create serious medication errors. Patients should not use a product if the package, prescription and supplied documentation contain inconsistent strength information.
Confirm the Dosage Form
The established reference product PEMAZYRE is supplied as an oral tablet.
However, the specific dosage form of a Pemitinib-branded product should be confirmed using its own packaging and official documentation.
A product’s dosage form affects how it should be administered and handled. Tablets, capsules, liquids and other formulations are not automatically interchangeable.
Patients should follow the instructions supplied with the actual medicine rather than assuming that another brand’s formulation instructions apply.
Manufacturer Verification
The manufacturer of the specific Pemitinib product has not been independently established in the information available for this website.
This information should not be guessed or inferred from the identity of the active ingredient.
PEMAZYRE is the established reference brand containing pemigatinib, and Incyte is associated with its development. This does not establish that Incyte manufactures Pemitinib.
The legal manufacturer should be identified through the product packaging, official product leaflet, regulatory documentation or confirmation from an authorized pharmaceutical organization.
Understanding Different Pharmaceutical Roles
Several organizations may participate in the development, production and supply of a medicine.
Developer or originator: The organization responsible for developing the active ingredient or original medicine.
Manufacturer: The organization responsible for producing the specific pharmaceutical product.
Brand owner: The legal entity that owns or controls a commercial product name.
Marketing authorization holder: The organization responsible for a product’s authorization in a particular regulatory jurisdiction.
Distributor: An organization involved in the authorized distribution of a pharmaceutical product.
Supplier: A party that supplies the medicine through a particular commercial or institutional channel.
These roles may belong to different organizations. One company’s involvement in the reference product does not establish its involvement in every alternative brand.
Batch or Lot Number
A batch or lot number identifies a particular production batch.
It helps manufacturers and authorized supply-chain organizations trace products through production and distribution.
When checking a Pemitinib package, the batch number should be visible and consistent with the accompanying documentation.
If the package contains an unclear, altered, missing or inconsistent batch number, the product should be referred to the dispensing pharmacy or appropriate pharmaceutical organization for verification.
Manufacturing and Expiry Dates
Manufacturing and expiry information helps establish the product’s production history and intended period of use.
Patients should check the expiry date before using a medicine.
A product should not be used after its expiry date. Packaging with erased, altered or conflicting date information should be treated as a reason for further investigation.
Storage conditions also matter. A medicine may be affected by exposure to unsuitable temperature, moisture or other environmental conditions.
Packaging and Label Inspection
The outer packaging and immediate container should be examined carefully.
Look for:
- Clear product identification.
- Correct stated strength.
- Active ingredient information.
- Manufacturer identification.
- Batch or lot number.
- Expiry information.
- Intact packaging.
- Appropriate tamper-evident features, where applicable.
- Legible instructions.
- Consistent product labeling.
Poor printing, damaged seals, unusual spelling errors or inconsistent package details may justify further investigation.
However, packaging appearance alone cannot prove that a medicine is genuine.
Regulatory Documentation
Regulatory authorization is specific to a medicine, manufacturer, formulation and jurisdiction.
A product’s registration in one country does not automatically establish authorization in another country.
For Pemitinib, the applicable registration status should be confirmed through the relevant national regulatory authority and official product documentation.
The registration of PEMAZYRE should not be presented as proof of Pemitinib’s registration.
Product Verification Checklist
| Verification item | What to confirm |
|---|---|
| Product name | Pemitinib |
| Active ingredient | Pemigatinib |
| Stated strength | 13.5 mg |
| Dosage form | Confirm from actual packaging |
| Manufacturer | Confirm from official documentation |
| Batch number | Present and consistent |
| Expiry date | Valid and legible |
| Packaging | Intact and consistent |
| Product leaflet | Matches the product |
| Regulatory status | Confirm for the relevant country |
What to Do If a Product Appears Suspicious
If a product has damaged packaging, inconsistent labeling, unclear manufacturer details or questionable batch information, patients should not rely on assumptions about its authenticity.
They should contact the dispensing pharmacy or authorized supplier and request appropriate verification.
Where a product-quality or authenticity concern remains unresolved, the relevant national medicines regulatory authority may provide further guidance.
Patients should not use a questionable medicine until its identity and suitability have been appropriately established.
Product Authenticity and Patient Safety
Authenticity is only one part of pharmaceutical safety.
A genuine medicine may still be unsuitable for a particular patient if it has not been prescribed appropriately, has expired, has been stored incorrectly or is being used outside its intended treatment instructions.
Pemigatinib requires specialist supervision, molecular eligibility assessment and regular monitoring.
Product verification should therefore be considered alongside appropriate prescribing and safe medicine handling.
Conclusion
Verifying Pemitinib 13.5 mg requires more than checking the product name or stated strength.
The active ingredient, dosage form, manufacturer, batch information, expiry date, packaging and applicable regulatory documentation should all be reviewed.
The specific manufacturer and regulatory status of Pemitinib must be established independently. Accurate verification helps support responsible pharmaceutical supply and patient safety.